Page 6 - Med Chem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Med chem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Med Chem Today - Breaking & Trending Today

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with .
Santhera Pharmaceuticals Holding AGMarch 3, 2021 GMT
Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to offer an alternative to current standard of care in DMD. ....

Switzerland General , United States , Eric Hoffman , Eva Kalias , Reveragen Biopharma , Reveragen Biopharma Inc , Life Science Alliance , Santhera Pharmaceuticals , National Institutes Of Health , Muscular Dystrophy Association United States , Head External Communications , Duchenne Research Fund , Foundation To Eradicate Duchenne , Santhera Pharmaceuticals Holding , European Commission Horizons , Chiesi Group , Us Department Of Defense , Med Chem , Science Alliance , Natl Acad Sci United , North American , Parent Project Muscular Dystrophy , Eradicate Duchenne , Save Our Sons , Action Duchenne , Duchenne Research ,